Fatty liver disease

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Retrieved on: 
Tuesday, January 10, 2023

The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical study which investigated the killing of cultured prostate cancer cells by rencofilstat in combination with a proteasome inhibitor, ixazomib.

Key Points: 
  • The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical study which investigated the killing of cultured prostate cancer cells by rencofilstat in combination with a proteasome inhibitor, ixazomib.
  • Proteosome inhibitors are a class of anti-cancer agents that are used for the treatment of multiple myeloma and other blood cancers.
  • The present study showed that rencofilstat could synergistically increase the proteotoxic stress and in vitro cancer killing properties of ixazomib.
  • In this preclinical study, rencofilstat and ixazomib were applied at low concentrations to several types of prostate cancer cell lines, and also to non-cancerous prostate cells.

Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding

Retrieved on: 
Monday, January 9, 2023

NJEDA’s NOL program enables qualified, New Jersey-based technology or biotechnology companies to sell net operating losses to unrelated profitable corporations.

Key Points: 
  • NJEDA’s NOL program enables qualified, New Jersey-based technology or biotechnology companies to sell net operating losses to unrelated profitable corporations.
  • This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development (“R&D”) or other allowable expenditures.
  • Alberta’s Innovation Employment Grant program encourages economic growth by supporting small and medium-sized businesses that invest in R&D with a grant worth up to 20% of qualifying expenditures.
  • The program promotes investment and diversification by rewarding all R&D spending in Alberta, Canada, regardless of the industry.

Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy

Retrieved on: 
Tuesday, January 10, 2023

In parallel, clinical results on the mode of action of TOTUM•63 will be obtained and communicated this year.

Key Points: 
  • In parallel, clinical results on the mode of action of TOTUM•63 will be obtained and communicated this year.
  • The results of the clinical bioavailability and mode of action study will be known early in the year.
  • Market research with healthcare professionals and consumers has helped establish the commercial strategy, combining medical recommendation and open access for consumers.
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.

The Worldwide Non-Alcoholic Steatohepatitis Industry is Projected to Reach $15 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

Elafibranor non-alcoholic steatohepatitis market is the fastest growing segment of global non-alcoholic steatohepatitis market in the forecasted period of 2023-2027 owing to positive impact of elafibranor in NASH treatment during clinical trials and drug's capability to reduce fat substance of liver, improving the conditions caused by NASH.

Key Points: 
  • Elafibranor non-alcoholic steatohepatitis market is the fastest growing segment of global non-alcoholic steatohepatitis market in the forecasted period of 2023-2027 owing to positive impact of elafibranor in NASH treatment during clinical trials and drug's capability to reduce fat substance of liver, improving the conditions caused by NASH.
  • By Application Type: The report provides the bifurcation of the market into two segments based on application type: treatment and diagnosis.
  • By Region: The report provides insight into the non-alcoholic steatohepatitis (NASH) market based on the regions namely North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
  • The Asia Pacific non-alcoholic steatohepatitis market is further divided into six regions on the basis of geographical operations, namely, China, India, Japan, Australia, South Korea and Rest of Asia Pacific, where China non-alcoholic steatohepatitis market held the largest share in Asia Pacific non-alcoholic steatohepatitis market.

Cambia Health Foundation Announces 12 New Sojourns Scholars

Retrieved on: 
Wednesday, January 11, 2023

PORTLAND, Ore., Jan. 11, 2023 /PRNewswire/ -- The Cambia Health Foundation has announced the selection of 12 emerging palliative care leaders for its Sojourns® Scholar Leadership Program. In its ninth year, this program identifies, cultivates and advances the next generation of palliative care leaders.

Key Points: 
  • PORTLAND, Ore., Jan. 11, 2023 /PRNewswire/ -- The Cambia Health Foundation has announced the selection of 12 emerging palliative care leaders for its Sojourns® Scholar Leadership Program.
  • Cambia Health Foundation recently opened the 2023 Sojourns Scholar Leadership Program call for applications , which will be the tenth and final cohort within the original program commitment of investing in up to 12 scholars per year for 10 years.
  • The Cambia Health Foundation launched the Sojourns Scholar Leadership Program in 2014 with the goal of advancing capacity, leadership and innovation in the field of palliative care.
  • To learn more about the individual scholars, please visit the Sojourns Scholars Scholar page on the Cambia Health Foundation website.

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

Retrieved on: 
Thursday, January 5, 2023

Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.

Key Points: 
  • Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
  • "After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round.
  • "The Series C/C+ financing is a significant milestone for HighTide.
  • It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

Retrieved on: 
Friday, January 6, 2023

The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.

Key Points: 
  • The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.
  • An MRI-PDFF conducted during screening confirmed that patients had NAFLD prior to obtaining a liver biopsy.
  • Each pathologist's scores showed a similar statistically significant magnitude of response at both doses for both liver biopsy endpoints.
  • The consensus read by the two central pathologists reinforced the positive results observed in the primary analysis (Tables 1-2).

Hepion Pharmaceuticals to Present Phase 2a Rencofilstat Multiomics Data at NASH-TAG 2023

Retrieved on: 
Thursday, January 5, 2023

“Multiomics integration provides a wholistic view of drug-disease interaction,” said Patrick Mayo, PhD, Hepion’s Senior Vice President, Clinical Pharmacology & Analytics.

Key Points: 
  • “Multiomics integration provides a wholistic view of drug-disease interaction,” said Patrick Mayo, PhD, Hepion’s Senior Vice President, Clinical Pharmacology & Analytics.
  • “It has allowed Hepion to uncover a complete network of rencofilstat activity in NASH and other fibrotic diseases.
  • Critically, it allows us to determine responders versus non-responders, key genetic drivers, and biomarkers for NASH and other disease states.
  • We have learned that rencofilstat alters key drivers in the currently understood NASH pathway with augmented activity outside of currently proposed paradigms.

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 5, 2023

FOSTER CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will provide an update on its pipeline and strategic priorities for 2023 during the Company’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023 at 9:00am PT.

Key Points: 
  • “2022 was a transformative year for Terns as we made important steps forward in our commitment to provide better, new medicines to people battling diseases with significant unmet medical needs.
  • “We expect 2023 to be an important year for Terns as we assess key inflection points for our clinical programs.”
    “Prior to our two recent financings, our cash runway supported three key clinical readouts from our three lead programs into 2025.
  • As such, it pains me to have to forsake my fellow cancer fighters in the United States because of economic policies that stifle medical innovation.
  • A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023

Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.

Key Points: 
  • It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
  • Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver.
  • Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
  • This underserved multibillion-dollar market creates significant opportunities for Clearmind to generate substantial revenues, should MEAI reach the market as an obesity treatment.